Quick Dispatch:
Your tirzepatide surmount Tirzepatide Demonstrates 94% Diabetes Reduction, 22% Weight Loss in SURMOUNT-1 Study orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surmount Tirzepatide Demonstrates 94% Diabetes Reduction, 22% Weight Loss in SURMOUNT-1 Study ships.
Need Help?
Questions about tirzepatide surmount Tirzepatide Demonstrates 94% Diabetes Reduction, 22% Weight Loss in SURMOUNT-1 Study, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surmount Tirzepatide Demonstrates 94% Diabetes Reduction, 22% Weight Loss in SURMOUNT-1 Study in your area.
01200-X/asset/a888810c-3ccf-4f48-b252-0dfdf720d276/main.assets/gr3_lrg.jpg)
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
21.42
Effect of tirzepatide in SURMOUNT-1 trial. (BMI: body mass index; CI:
21.09
Lilly Shows Tirzepatide Superiority in SURMOUNT-3 and 4
25.70
Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity
27.41
In the SURMOUNT-5 phase 3b trial involving adults with obesity without type 2 diabetes, tirzepatide was superior to semaglutide in reducing body weight and waist circumference. Full trial results and Research Summary:
23.97
SURMOUNT-3 study design This is a phase 3, multicenter, randomized,
19.98
ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide sustains weight loss long term
25.36
